Молекулярные тест-системы гибридизационного анализа в диагностике лекарственной чувствительности M. tuberculosis к фторхинолонам и инъекционным препаратам

В работе представлены данные тестирования лекарственной чувствительности (ЛЧ) клинических изолятов M. tuberculosis к фторхинолонам и инъекционным препаратам с помощью молекулярно-генетических тест-систем и фенотипических методов. Показаны диагностические возможности гибридизационных технологий «ТБ-ТЕСТ» и GenoType MTBDRsl v.2 в определении генетических детерминант устойчивости изолятов с множественной, пре-широкой и широкой лекарственной устойчивостью.

1. Мирзабеков А.Д. Биочипы в биологии и медицине XXΙ века // Вестник РАН. – 2003. – Т. 73. – № 5. – С. 412.

2. Приказ № 951 Минздрава России от 29 декабря 2014 г. «Об утверждении методических рекомендаций по совершенствованию диагностики и лечения органов дыхания». – М., 2014. – 41 с.

3. Руководство по интерпретации и отчетности для лабораторного персонала и врачей. Тесты молекулярной гибридизации с типоспецифическими зондами для выявления лекарственно-устойчивого туберкулеза // www.stoptb.org/wg/gli

4. Ajileye A., Alvarez N., Merker M et al. Some synonymous and nonsynonymous gyrA mutations in Mycobacterium tuberculosis lead to systematic falsepositive fluoroquinolone resistance results with the Hain GenoType MTBDRsl Assays // Antimicrob. Agents Chemother. – 2017. – Vol. 61, № 4. – e02169-16.

5. Aubry A., Veziris N., Cambau E. et al. Novel gyrAse mutations in quinolone-resistant and-hypersusceptible clinical isolates of Mycobacterium tuberculosis: functional analysis of mutant enzymes // Antimicrob. Agents Chemother. – 2006. – Vol. 50. – P. 104-112.

6. Brossier F., Guindo D., Pham A. et al. Performance of the new version (v. 2.0) of the GenoType MTBDRsl test for detection of resistance to second-line drugs in multidrug-resistant Mycobacterium tuberculosis complex strains // J. Clin. Microbiol. – 2016. – Vol. 54. – P. 1573-1580.

7. Chakravorty S., Lee J.S., Cho E.J/ et al. Genotypic susceptibility testing of Mycobacterium tuberculosis isolates for amikacin and kanamycin resistance by use of a rapid sloppy molecular beacon-based assay identifies more cases of low-level drug resistance than phenotypic Lowenstein-Jensen testing // J. Clin. Microbiol. – 2015. – Vol. 53, № 1. – Р. 43-51.

8. Coeck N., Jong B.C., Diels M. et al. Correlation of different phenotypic drug susceptibility testing methods for four fluoroquinolones in Mycobacterium tuberculosis // J. Antimicrob. Chemother. – 2016. – Vol. 71, № 5. – P. 1233-1240.

9. Gardee Y., Dreyer A.W., Koornhof H.J. et al. Evaluation of the GenoType MTBDRsl version 2.0 Assay for second-line drug resistance detection of Mycobacterium tuberculosis isolates in South Africa / J. Clin. Microbiol. – 2017. – Vol. 55. – P. 791-800.

10. Georghiou S.B., Magana M., Garfein R.S. et al. Evaluation of genetic mutations associated with Mycobacterium tuberculosis resistance to amikacin, kanamycin and capreomycin: a systematic review // PLoS One. – 2012. – Vol. 7, № 3. – e33275.

11. Hillemann D., Rüsch-Gerdes S., Richter E. Feasibility of the Geno Type® MTBDRsl Assay for fluoroquinolone, amikacin/capreomycin, and ethambutol resistance testing of Mycobacterium tuberculosis strains and in clinical specimens // J. Clin. Microbiol. – 2009. – Vol. 47. – P. 1767-1772.

12. Kambli P., Ajbani K., Nikam C. et al. Correlating rrs and eis promoter mutations in clinical isolates of Mycobacterium tuberculosis with phenotypic susceptibility levels to the second-line injectables // Int. J. Mycobacteriol. – 2016. – Vol. 5, № 1. – P. 1-6.

13. Lasunskaia E., Ribeiro S.C., Manicheva O. et al. Emerging multidrug resistant Mycobacterium tuberculosis strains of the Beijing genotype circulating in Russia express a pattern of biological properties associated with enhanced virulence // Microbes Infect. – 2010. – Vol. 12, № 6. – P. 467-475.

14. Ling D.I., Zwerling A.A., Pai M. Rapid diagnosis of drug-resistant TB using line probe assays: from evidence to policy // Expert Rev. Respir. Med. – 2008. – Vol. 2. – P. 583-588. Magnet S., Blanchard J.S. Molecular insights into aminoglycoside action and resistance // Chem. Rev. – 2005. – Vol. 105, № 2. – P. 477-498.

15. Malik S., Willby M., Sikes D. et al. New insights into fluoroquinolone resistance in Mycobacterium tuberculosis: functional genetic analysis of gyrA and gyrB mutations // PLoS One. – 2012. – Vol. 7, № 6. – e39754.

16. Maus C.E., Plikaytis B.B., Shinnick T.M. Molecular analysis of cross-resistance to capreomycin, kanamycin, amikacin, and viomycin in Mycobacterium tuberculosis // Antimicrob. Agents Chemother. – 2005. – Vol. 49, № 8. – P. 3192-3197.

17. Miotto P., Tessema B., Tagliani E. et al. A standardised method for interpreting the association between mutations and phenotypic drug resistance in Mycobacterium tuberculosis // Eur. Respir. J. – 2017. – Vol. 50, № 6. – 1701354.

18. Narvskaya O., Otten T., Limeschenko E. et al. Nosocomial outbreak of multidrug-resistant tuberculosis caused by a strain of Mycobacterium tuberculosis W-Beijing family in St. Petersburg, Russia // Eur. J. Clin. Microbiol. Infect. Dis. – 2002. – Vol. 21, № 8. – P. 596-602.

19. Reeves A.Z., Campbell P.J., Sultana R. et al. Aminoglycoside cross-resistance in Mycobacterium tuberculosis due to mutations in the 5‘ untranslated region of whiB7 //Antimicrob. Agents Chemother. – 2013. – Vol. 57, № 4. – P. 1857-1865.

20. Schön T., Miotto P., Köser C.U. et al. Mycobacterium tuberculosis drug resistance testing: challenges, recent developments and perspectives // Clin. Microbiol. Infect. – 2017. – Vol. 23, № 3. – P. 154-160.

21. Siddiqi S. H., Rusch-Gerdes S., Alexander H. et al. MGIT Procedure Manual for BACTECТМMGITТМ960 TB System (Also applicable for Manual MGIT) – 2006. [Электронный ресурс] https://www.finddx.org/wp-content/uploads/2016/02/mgit_manual_nov2006.pdf (Дата обращения 20.09.2022).

22. Takiff H., Salazar L., Guerrero C. et al. Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations // Antimicrob. Agents Chemother. – 1994. – Vol. 38, № 4. – P. 773-780.

23. Wang J.-Y., Lee L.-N., Lai H.-C. et al. Fluoroquinolone resistance in Mycobacterium tuberculosis isolates: associated genetic mutations and relationship to antimicrobial exposure // J. Antimicrob. Chemother. – 2007. – Vol. 59, № 5. – P. 860-865.

24. World Health Organization. The use of molecular line probe assays for the detection of resistance to second-line antituberculosis drugs. Policy guidance. – WHO.: Geneva, Switzerland, 2016. – 52 p.

25. World Health Organization. Policy guidance on drug-susceptibility testing (DST) of second-line antituberculosis drugs [Электронный ресурс]. – 2008. – Режим доступа: https://apps.who.int/iris/bitstream/handle/10665/70500/WHO_HTM_TB_2008.392_eng.pdf?sequence=1

26. Zaunbrecher M.A., Sikes Jr. R.D., Metchock B. et al. Overexpression of the chromosomally encoded aminoglycoside acetyltransferase eis confers kanamycin resistance in Mycobacterium tuberculosis // Proc. Natl. Acad. Sci. USA. – 2009. – Vol. 106, № 47. – P. 20004-20009.

27. Zhang Z., Liu M., Wang Y. et al. Molecular and phenotypic characterization of multidrug-resistant Mycobacterium tuberculosis isolates resistant to kanamycin, amikacin, and capreomycin in China // Eur. J. Clin. Microbiol. Infect. Dis. – 2014. – Vol. 33, № 11. – P. 1959-1966.

28. Zimenkov D.V., Kulagina E.V., Antonova O.V. et al. Simultaneous drug resistance detection and genotyping of Mycobacterium tuberculosis using a low-density hydrogel microarray // J. Antimicrob. Chemother. – 2016. – Vol. 71, № 6. – P. 1520-1531.